Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen.

Abstract

The influence of obesity on the distribution or clearance of lorazepam and oxazepam, two benzodiazepines biotransformed by glucuronide conjugation, was studied in a series of obese subjects (mean weight 113 kg; mean percent IBW 179%) and healthy controls of normal body habitus matched for age and sex. Overweight subjects and controls received 2 to 3 mg of lorazepam intravenously or 30 mg of oxazepam orally. Absolute Vd in obese compared to control subjects was increased for both lorazepam (131 vs. 77 L, p less than 0.001) and oxazepam (97 vs. 38 L, p less than 0.001). When normalized to body weight, Vd/kg was similar for both drugs. Total metabolic clearance was similarly increased in the obese cohort for lorazepam (102 vs. 63 ml/min, p less than 0.005) and oxazepam (157 vs. 50 ml/min, p less than 0.001). Again, when normalized to body weight, clearance per kilogram was similar for both drugs. Since both Vd and clearance increased with body weight, elimination half-life (dependent on both Vd and clearance) was not significantly different in obese subjects (lorazepam 16.5 vs. 14.9 hr; oxazepam 7.7 vs. 8.9 hr). A random subgroup of obese and control subjects received a single intravenous dose of acetaminophen, also biotransformed by conjugation. Acetaminophen clearance was significantly correlated with that of lorazepam (r = 0.59, p less than 0.01) and oxazepam (r = 0.87, p less than 0.001), and clearance of LRZ and OXZ were similarly intercorrelated (r = 0.72, p less than 0.01). Thus obesity is associated with enhanced capacity for biotransformation of drugs via glucuronide conjugation. conjugating capacity increases in proportion to TBW and is consistent among drugs biotransformed by this mechanism.

• Authors: D R Abernethy, D J Greenblatt, M Divoll, R I Shader
• Journal: The Journal of laboratory and clinical medicine (J Lab Clin Med) Vol. 101 Issue 6 Pg. 873-80 (Jun 1983) ISSN: 0022-2143 [Print] United States
• PMID: 6133901 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anti-Anxiety Agents
• Glucuronates
• Acetaminophen
• Oxazepam
• Lorazepam

Topics

• Acetaminophen (metabolism)
• Adult
• Aged
• Anti-Anxiety Agents (metabolism)
• Female
• Glucuronates (metabolism)
• Humans
• Lorazepam (metabolism)
• Male
• Middle Aged
• Obesity (metabolism)
• Oxazepam (metabolism)